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ABSTRACT 
Studies have previously shown sugammadex works faster and more effectively than neostigmine/glycopyrrolate at reversal of 
neuromuscular blockade by rocuronium and vecuronium. The purpose of this quality improvement study was to evaluate for differences 
in patient time spent in the operating room (OR), post-anesthesia care unit (PACU), and patient responsiveness between the 
sugammadex and neostigmine/glycopyrrolate groups at a small surgical center. Additionally, a cost analysis was conducted to assess 
potential savings associated with sugammadex use, taking into account the differences in OR time, PACU time, and medication 
acquisition cost. We conducted a prospective analysis of OR time, PACU time, and responsiveness for a total of 152 patients, 76 patients 
receiving neostigmine/glycopyrrolate and 76 patients receiving sugammadex, undergoing planned surgery over an 8-week period. We 
identified an average decrease in total OR time of 6 minutes in the sugammadex group (neostigmine/glycopyrrolate [Mean: 86 min, 
Median: 77 min, Range 32-211 min] vs sugammadex [Mean: 80 min, Median: 77 min, Range 40-150 min]). Furthermore, there was an 
average decrease in total PACU time of 6 minutes in the sugammadex group (neostigmine/glycopyrrolate [Mean: 60 min, Median: 56 
min, Range 32-154 min] vs sugammadex [Mean: 54 min, Median: 51 min, Range: 28-94 min]). Additionally, the percent of patients fully 
awake at the end of PACU stay was higher in the sugammadex group than the neostigmine/glycopyrrolate group (86% vs 79% 
respectively). Cost was evaluated for generating hypotheses. The additional cost of using sugammadex was estimated at $77 per 
person when compared to neostigmine/glycopyrrolate. However, if the use of sugammadex decreased the time in OR and PACU by an 
average of 12 minutes per patient, it is possible that it could provide a potential savings of $579 per patient after estimating a soft 
savings of reduced OR, PACU, and staff time. Overall cost saving per patient with sugammadex, which was calculated after subtracting 
additional medication acquisition cost, is $502. It is possible that if this value is extrapolated to 988 patients, this might suggest a 
potential cost savings of $495,976 per year. We hope this study provokes future research to determine if Sugammadex is a potentially 
viable economical option for the routine reversal of neuromuscular blockade. 
 
Keywords: sugammadex, neostigmine, glycopyrrolate, post-anesthesia care unit, operating room, economic evaluation, cost analysis 
 
 
INTRODUCTION 
Neuromuscular blocking agents (NMBAs) are used as an adjunct 
to anesthesia prior to surgery to paralyze vocal cords for 
intubation. NMBAs can be divided into two categories, 
depolarizing and nondepolarizing. Depolarizing NMBAs agonize 
cholinergic receptors of the neuromuscular junction, initially 
causing contraction followed by relaxation.1 In contrast, 
nondepolarizing NMBAs compete with acetylcholine receptors 
and inhibit their action.2  
 
Reversal of neuromuscular blockade (NMB) can occur by 
spontaneous recovery or in routine surgical practice by 
administration of reversal agents. Residual muscular paralysis, 
a persistent post-operative muscle weakness, is a dangerous 
risk factor for anesthesia related morbidity and mortality 
including airway obstruction, reintubation, hypoxia, atelectasis, 
aspiration, pneumonia, and pulmonary edema.3 Furthermore, 
postoperative residual paralysis can decrease the efficiency of 
the institution by delaying transfer to the recovery room.4  
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Neostigmine has been used routinely as a reversal agent for 
neuromuscular blockade since 1931.5 Neostigmine works by 
inhibiting destruction of acetylcholine, which also results in 
unwanted muscarinic side effects including bronchospasm, 
intestinal hypermotility, and bradycardia.6 Glycopyrrolate is 
administered in conjunction with neostigmine to minimize 
these adverse side effects by competitively binding to the 
muscarinic receptors and inhibit cholinergic transmission.7  
 
Sugammadex was FDA approved in 2015 and has a novel 
mechanism of action. It works by selectively binding and 
forming a complex with the NMBAs (rocuronium and 
vecuronium) in the plasma, reducing the amount of NMBA 
available in the neuromuscular junction, reversing their 
effects.8  
 
Studies have previously shown that sugammadex works faster 
and more effectively than neostigmine/glycopyrrolate for 
routine reversal of neuromuscular blockade by rocuronium and 
vecuronium.9,10 Train-of-four (TOF) twitch stimulation is a 
standardized clinical tool that is used to assess the degree of 
neuromuscular blockade in the anesthetized patient and 
involves stimulating the ulnar nerve with four supramaximal 
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stimuli separated by 0.5 seconds.11 Twitches on a TOF pattern 
fade as relaxation increases and enables the observer to 
compare T4 (fourth twitch of the TOF) versus T1 (first twitch of 
the TOF). Train-of-four ratio (TOFR) refers to T1 to T4 ratio with 
a satisfactory recovery from the neuromuscular block observed 
at TOFR >0.9.11  
 
Hristovska AM et al., conducted a meta-analysis comparing 
sugammadex to neostigmine with and without glycopyrrolate 
or atropine.9 Among the 41 studies (n=4206) included in this 
meta-analysis, 12 trials (n=949) were used to assess the primary 
outcome (recovery times to train-of-four ratio [TOFR] > 0.9) and 
28 trials were used to assess the secondary outcomes (risk of 
adverse events and risk of serious adverse events).9 This meta-
analysis supported sugammadex was faster than neostigmine 
in reversing NMB from the second twitch (T2) to TOFR > 0.9 
[sugammadex 2 mg/kg (1.96 minutes) vs neostigmine 0.05 
mg/kg (12.87 minutes)] and in reversing rocuronium-induced 
deep NMB from post-tetanic count (PTC) 1 to 5 to TOFR > 0.9 
[sugammadex 4 mg/kg (2.9 minutes) vs neostigmine 0.07 mg/kg 
(48.8 minutes)].9 Furthermore, patients receiving sugammadex 
had 40% fewer adverse events (159 composite adverse events 
per 1000 cases) compared with those given neostigmine alone 
(283 composite adverse events per 1000 cases).9 Specifically, 
sugammadex showed significantly less risk of bradycardia 
[sugammadex (13 per 1000) vs neostigmine (84 per 1000)], 
postoperative nausea and vomiting [sugammadex, (68 per 
1000) vs neostigmine (131 per 1000)], and postoperative 
residual paralysis [sugammadex (52 per 1000) vs neostigmine 
(131 per 1000)].9 Application of trial sequential analysis (TSA) 
indicated superiority of sugammadex for recovery time and 
adverse events.9  
 
In a multicenter, randomized, controlled trial conducted from 
13 sites in Europe, patients were randomized to receive either 
sugammadex (2 mg/kg) or neostigmine (0.05 mg/kg) plus 
glycopyrrolate (0.01 mg/kg) IV.10 The geometric mean time to 
recovery of the TOF ratio to 0.9 was significantly faster with 
sugammadex compared with neostigmine [2.7 min versus 17.9 
min; P < 0.0001; two-way ANOVA]. 10 Although there is sufficient 
evidence to support superiority of sugammadex over 
neostigmine and glycopyrrolate, there have been no studies to 
evaluate the economic value or indirect financial benefits of 
sugammadex use. The aim of this research was to identify if 
those characteristics making sugammadex more efficient could 
show a financial benefit. Despite several studies including a 
meta-analysis conducted by Carron et al. that reported 
sugammadex was associated with a significantly faster 
discharge from the OR to the PACU (mean difference 
[MD]=22.14 min) and the PACU to the surgical ward (MD=16.95 
min), many institution have placed restrictions around 
sugammadex use due to the differences in drug cost.12  
Sugammadex has a higher average wholesale price than 
neostigmine and glycopyrrolate combined.6,7,8 However, when 
evaluating the pharmacoecnomics of sugammadex, we believe 
it is vital to not only to consider drug acquisition cost, but to 
consider the financial impact of OR room cost, PACU room cost, 
and staff salary. It is vitally important to close the gap in 
knowledge regarding the economic impact of sugammadex use, 
as facilities will likely continue to restrict this safer and more 
efficacious medication, which could ultimately impact patient 
safety. We hypothesized that the increased cost of 
sugammadex could be justified by the estimated savings from a 
decrease in PACU time, OR time, and staff time. 
 
METHODS 
Setting 
This quality improvement study was conducted at a small 
surgical hospital that provides clinical services to the Texas 
Panhandle and the surrounding tri-state area. As a quality 
improvement project for formulary restriction, we were not 
required to submit for IRB approval. Types of major surgeries 
performed at this hospital include arthroscopy/arthroplasty 
(e.g., knee, hip, disk), cholecystectomy, hysterectomy, hernia 
repair, salpingectomy, appendectomy, laparoscopy, 
discectomy, and cystectomy. Prior to our study, use of 
sugammadex was highly scrutinized due to its high drug 
acquisition cost and no internal evaluations to justify its use 
over neostigmine/glycopyrrolate.  
 
Data Collection 
We designed our study in a prospective manner due to 
insufficient data available to conduct a retrospective analysis. 
Inclusion criteria included any adult patient scheduled for 
surgery that received either sugammadex or 
neostigmine/glycopyrrolate without use of any other 
antimuscarinic (e.g., atropine). Exclusion criteria included any 
patient with a known allergy to sugammadex, neostigmine, or 
glycopyrrolate, and anyone who received another 
antimuscarinic (e.g., atropine) during the surgical procedure. 
The study period included data from September through 
November 2017. We collected data for two groups, separated 
by either treatment with neostigmine/glycopyrrolate or 
sugammadex, including an equal number of patients in each 
group. At the termination of this study, a total of 152 patients, 
76 patients from sugammadex group and 76 patients from 
neostigmine/glycopyrrolate group, were included. During the 
collection period a pharmacist, a pharmacy resident, and a 
pharmacy technician collected and de-identified the data by 
reviewing patients’ charts and using Docuware, a document 
management software for workflow automation (DocuWare, 
Germering, Germany). Operating room (OR) time, post 
anesthesia care unit (PACU) time, responsiveness, demographic 
information (e.g., age, sex), American Society of 
Anesthesiologists (ASA) scoring, and wound score were 
recorded for each patient. OR start time is the “enter time” of 
the patient into the OR. OR stop time is the time that the 
complete closure of the wound has occurred, as documented 
by a surgical nurse. OR time refers to the difference between 
the OR start and stop times. PACU start time is the time that the 
patient was transferred from the OR to the PACU. PACU stop 
time is the time that the patient is discharged from the PACU 
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after recovery. PACU time refers to the difference between the 
PACU start and stop times. We assessed patient responsiveness 
at the end of PACU stay by physician documentation divided 
into three categories, not responding, arousable, and fully 
awake. ASA score is a global score that assesses the physical 
status of patients before surgery and ranges from 1-5. 1 is 
defined as a normal healthy patient, 2 is defined as a patient 
with mild systemic disease, 3 is defined as a patient with severe 
systemic disease, 4 is defined as a patient with severe systemic 
disease that is a constant threat to life, and 5 is defined as a 
moribund patient who is not expected to survive.13 Wound 
score is based on the surgical classification ranges from 1 to 4, 
with 1 defined as a clean wound with no infection or 
inflammation, 2 defined as a clean-contaminated wound with 
no unusual contamination, 3 defined as a contaminated, open, 
fresh, accidental wound, and 4 defined as a dirty, old traumatic 
wound with and without existing infection or perforation.14  
 
Cost Assessment 
A cost assessment was conducted to generate hypotheses 
about sugammadex use being economically viable. We 
evaluated potential soft savings by estimating a potential 
savings by taking into account the differences in OR time, PACU 
time, medication acquisition cost, and anesthesiologist salary. 
For this research, using our actual PACU, OR, and 
anesthesiologist cost for publication was not permissible. We 
utilized previous publications to assign monetary values for our 
calculations of OR, PACU, and anesthesiologist cost per 
minute.15,16 Estimation of 988 patients per year was calculated 
using 152 patients that had surgery at our institution over an 8 
week period, then multiplied by 6.5 to extrapolate to patients 
per year. We would have liked to include other factors such as 
cost associated with adverse events from residual paralysis, but 
we were unable to include due to lack of data.  
  
Data Analysis and Statistical Analysis 
Descriptive analysis was carried out using Excel 2013. A 
descriptive analysis of documented data was performed to 
evaluate the differences in time spent in the OR, time spent in 
the PACU, and patient responsiveness between the 
sugammadex and neostigmine/glycopyrrolate groups. 
Statistical analysis was carried out by GraphPad Prism 7 
(GraphPad Software Inc., San Diego, California, USA). Student’s 
unpaired t-test was used to compare time spent in the OR and 
PACU between the sugammadex group and the 
neostigmine/glycopyrrolate group. Fisher’s exact test was used 
to compare the patient responsiveness between groups.  
 
RESULTS 
Demographic representation was similar in both treatment 
groups, with similar sample size, average age, and sex 
distribution (Figure 1). Type of surgeries performed were 
similar in both treatment groups (Table 1). Furthermore, both 
groups had similar baseline physical status classifications based 
on the ASA scoring system [2.25 (neostigmine/glycopyrrolate) 
vs 2.23 (sugammadex)] (Figure 1). We included average wound 
score to assess severity of the surgical wounds, and both groups 
were similar [1.34 (neostigmine/glycopyrrolate) vs 1.23 
(sugammadex)] (Figure 1).  
 
Data analysis demonstrated that average OR time was 6 
minutes shorter in the sugammadex group than in the 
neostigmine/glycopyrrolate group [(Mean: 80 min; Median: 77 
min; Range 40-150 min; 95% CI 74-86 min vs Mean: 86 min; 
Median: 77 min, Range: 32-211 min; 95% CI 77-95 min, 
respectively) (p=0.2747, unpaired t-test)] (Table 2, Figure 2). 
Additionally, average PACU time was 6 minutes shorter             for 
the sugammadex group compared to the 
neostigmine/glycopyrrolate group [(Mean: 54 min; Median: 51 
min; Range 28-94 min; 95% CIs 50-59 min vs Mean: 60 min; 
Median: 56 min; Range: 32-154 min; 95% CIs 55-65 min 
respectively) (p=0.1054, unpaired t-test)] (Table 2, Figure 3). 
Percentage of patients fully awake at the end of PACU stay was 
higher in the sugammadex group (86%) than the 
neostigmine/glycopyrrolate group (79%) (p=0.3963, fisher’s 
exact test) (Table 2, Figure 4). For the patients who were either 
arousable or not responding, appropriate treatment was given. 
 
Estimated facility and personnel cost savings for sugammadex 
due to less time needed for anesthesiologist/facility use was 
$579 [$48 ($4/min x 12 minutes, Anesthesiologist) + $372 
($62/min x 6 minutes, OR room) + $159 ($26.5/min x 6 minutes, 
PACU room)] (Figure 5). Estimated drug acquisition cost for 
sugammadex, for a 75 kg patient, was $77 more for 
sugammadex than neostigmine/glycopyrrolate [$208 
(sugammadex) - $131 (neostigmine/glycopyrrolate)] (Figure 6). 
For sugammadex, a single dose of 2-4 mg/kg was administered, 
and we chose 3 mg/kg for cost analysis because exact dose for 
each patient was not retrievable. For neostigmine, doses 
ranged between 0.03-0.07 mg/kg and we chose 0.05 mg/kg 
with 0.75 mg for glycopyrrolate for cost analysis because exact 
dose for each patient was not retrievable (Table 3). We rounded 
doses to vials required to account for practical application, as 
these medications are only available as single dose vials. 
Overall, potential cost savings per patient with sugammadex, 
which was calculated after subtracting additional medication 
acquisition cost, was $502 [$579 - $77] (Figure 7). If 
extrapolated to one year, this potential for soft-savings could 
equate to $495,976 annually [152 patients per 8 week study 
period; 152 x 6.5 = 988 patients; $502 x 988 = $495,976].  
 
DISCUSSION 
Our findings of a decrease in PACU time and OR time associated 
with sugammadex, although not statistically significant, are 
consistent with previous literature.12 Increase in PACU time and 
OR time in neostigmine/glycopyrrolate could be due to onset of 
action being slower than sugammadex (neostigmine: 10 to 30 
minutes, sugammadex: <3 minutes).6,7,8 This could impact PACU 
time and OR time due to slower reversal of neuromuscular 
blockade requiring longer stay. Other factors that could impact 
PACU and OR time include increase in patients experiencing 
adverse events such as bradycardia. Furthermore,  
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the maximum OR time and PACU time of 
neostigmine/glycopyrrolate was 60 minutes higher than that of 
sugammadex (211 minutes vs 151 minutes and 154 minutes vs 
94 minutes, respectively). Yet, it has been noted that the type 
of surgeries performed were similar in both treatment groups, 
with the top 5 surgical types being arthroscopy, arthroplasty, 
hernia, cholecystectomy, and cystectomy. Having shorter OR 
and PACU times allows for faster turnover, that is ultimately 
beneficial to the patients and the institution. Though we 
evaluated 152 patients for all other parameters, 2 were 
excluded (1 from each group) from PACU analysis due to PACU 
time longer than 200 minutes and discrepancies in 
documentation.  
Our study had several limitations. Innately there were many 
challenges when preparing the financial assessment. One of the 
limitations involves the estimation of drug acquisition cost. The 
exact weight and specific drug dosages were not retrievable, 
thus we used an estimated weight of 75 kg to calculate drug 
doses for cost evaluation. Additionally, using drug cost based 
on average wholesale price provides a good estimate; it may 
differ slightly from the actual hospital drug acquisition cost. A 
major limitation of our study is the estimated cost savings 
associated with minutes of OR and PACU time. We considered 
anesthesiologist time by using a conservative salary of 
approximately $340,000 per year. This could vary widely 
depending on actual hours worked, differences in salary, and 
utilization of nurse anesthetists. For the OR and PACU room 
costs per minute, a conservative estimate was used, but we 
were only able to find one single source for each estimate.15,16 
Therefore, estimation of cost could vary significantly by 
institution. Another limitation of our study is not documenting 
side effects (e.g., residual paralysis) associated with the use of 
each treatment, the known factor to increase an additional cost 
of care, and not including this in our cost analysis.   
 
For future research, it would be beneficial to include adverse 
events to identify which patient populations are most likely to 
benefit from use of sugammadex.  
 
Despite of these limitations, we hope that findings from this 
innovative study have a positive impact in suggesting that 
although initial acquisition of sugammadex cost is higher – it 
will likely pay for itself with increased efficiency of the OR and 
PACU. With the economic benefits of using sugammadex over 
neostigmine/glycopyrrolate still unknown, our study can serve 
as a good template for other institutions planning to conduct 
similar research to help evaluate the economic impact of 
sugammadex use.17 
 
CONCLUSION 
Previous studies have shown that sugammadex is faster and 
more efficient at reversal of neuromuscular blockade than 
neostigmine and glycopyrrolate. Our observation suggests a 12 
minute reduction in time per surgical case possibly due to 
sugammadex use (6 minute decrease in OR time and a 6 minute 
decrease in PACU time). Sugammadex has a higher drug 
acquisition cost, however, when considering the potential 
facility and personnel cost savings, use of sugammadex could 
be justified at our institution. Future research still needs to be 
directed at identifying patient populations most likely to benefit 
from use of sugammadex, to assess the number of patients 
suffering from side effects that are known to increase economic 
burden to the institution, and to conduct cost-analysis to assess 
how reduced side effects can contribute to cost savings.  
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Figure 1. Demographic Representation of Two Treatment Groups 
 
*Neo/Glyco: Neostigmine/Glycopyrrolate 
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Table 1. Types of Surgeries Conducted of Two Treatment Groups 
 
*Data summarized as the actual number of patient/total  
number of patients (% of surgery) for each row 
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Table 2. Summary of Average OR Time, Average PACU Time, 
and Responsiveness in Two Treatment Groups 
 
 
 
 
 
 
Table 3. Dosage for Neostigmine/Glycopyrrolate and Sugammadex
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Figure 2. Patient Distribution of OR Time in Two Treatment Groups* 
 
*Neo/Glyco: Neostigmine/Glycopyrrolate 
 
 
 
 
 
 
Figure 3. Patient Distribution of PACU Time in Two Treatment Groups*, § 
 
*Neo/Glyco: Neostigmine/Glycopyrrolate 
§ 1 patient from each group was excluded from analysis due to incomplete documentation. 
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Figure 4. Percentage of Responsiveness in Two Treatment Groups 
*Neo/Glyco: Neostigmine/Glycopyrrolate 
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  P value
  P value summary
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Data analyzed
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Figure 5. Estimated Facility and Personnel Cost Saving Per Patient 
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Figure 6. Estimated Drug Acquisition Cost between Two Treatments 
*Neo/Glyco: Neostigmine/Glycopyrrolate 
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Figure 7. Overall cost saving per patient 
 
 
Drug Acquisition Cost between Two Treatments
Actual Cost Saving*
$502
$77
*$579 (Estimated Facility and Personnel Cost Saving)-$77
(Drug Acquisition cost) = $502 (Actual Cost Saving)]
$579 (Total)
 
§152 patients per 8 week study period; 1 year ~ 52 weeks; 52/8 = 6.5; 152 x 6.5 = 988 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
